Fig. 1: The antitumour effect of TCC treatment in clinical practice andexperimental verification in a mouse PDX model. | Cell Death & Disease

Fig. 1: The antitumour effect of TCC treatment in clinical practice andexperimental verification in a mouse PDX model.

From: Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma

Fig. 1

a Kaplan‒Meier survival analysis demonstrated that the study cohort treated with TCC showed better survival. b The study cohort demonstrated a better survival ratio at three timepoints. c AFP and PIVKA-II expression were significantly decreased in the study cohort. d Patient #1 underwent 5 courses of TCC therapy, a significant decrease in tumour number and remarkable tumour volume shrinkage were found by CT scan. e Patient #2 underwent 3 courses of TCC therapy, remarkable tumour volume shrinkage was found by CT scan. f. g Thirty-six PDX models were established by implanting patient-derived tumour cells subcutaneously into the flanks of BALB/C mice. Seven days later, all mice developed tumours of comparable size and were then divided into six groups and injected separately with DMSO, THA, CAR, CAN, TC, or TCC. Comparing tumour size, tumour volume (h) and tumour weight (i), monotherapy suppressed tumour growth to some extent, but the combination of drugs, especially the TCC combination, further delayed it. j, k Colony formation assay results. The addition of THA or THA and CAN had no further impact on cell viability in either of the six types of HCC cells. Tukey’s post hoc test (level of significance: ***P < 0.001; **P < 0.01; ns, P > 0.05).

Back to article page